Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements.
Material Changes
The only material change disclosed is a transaction by Mr. S M Bicknell, a person discharging managerial responsibility. On October 7, 2013, he purchased 24 Ordinary Shares at a price of 1549.50 pence per share. This purchase resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 7, 2013.
- Individual: Mr. S M Bicknell (Person Discharging Managerial Responsibility).
- Transaction Type: Purchase of 24 Ordinary Shares via dividend re-investment.
- Price: 1549.50 pence per share.
- Notification Date: October 8, 2013.